Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.
Seliger
Stephen
S
Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland, USA. sseliger@medicine.umaryland.edu
Fox
Kathleen M
KM
Gandra
Shravanthi R
SR
Bradbury
Brian
B
Hsu
Van Doren
VD
Walker
Loreen
L
Chiou
Chiun-Fang
CF
Fink
Jeffrey C
JC
D000368:Aged; D000553:Ambulatory Care; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D015415:Biomarkers / Q000097:blood; D001803:Blood Transfusion; D016009:Chi-Square Distribution; D002908:Chronic Disease; D004334:Drug Administration Schedule; D004920:Erythropoiesis / Q000187:drug effects*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage*; D006454:Hemoglobins / Q000378:metabolism; D006760:Hospitalization; D006801:Humans; D053208:Kaplan-Meier Estimate; D007674:Kidney Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D057216:Propensity Score; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D006397:Hematinics; D006454:Hemoglobins